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Abstract
Background: Somatic mutations in the ubiquitin-specific 
protease 8 (USP8) gene have recently been shown to occur 
in ACTH-secreting pituitary adenomas, thus calling attention 
to the ubiquitin system in corticotrope adenomas. Objec-
tives: Assess the consequences of USP8 mutations and es-
tablish the role of ubiquitin on ACTH turnover in human 
ACTH-secreting pituitary adenomas. Methods: USP8 muta-
tion status was established in 126 ACTH-secreting adeno-
mas. Differences in ACTH secretion and POMC expression 
from adenoma primary cultures and in microarray gene ex-
pression profiles from archival specimens were sought ac-
cording to USP8 sequence. Ubiquitin/ACTH coimmunopre-
cipitation and incubation with MG132, a proteasome inhibi-
tor, were performed in order to establish whether ubiquitin 
plays a role in POMC/ACTH degradation in corticotrope ad-
enomas. Results: USP8 mutations were identified in 29 ade-
nomas (23%). Adenomas presenting USP8 mutations secret-
ed greater amounts of ACTH and expressed POMC at higher 
levels compared to USP wild-type specimens. USP8 mutant 
adenomas were also more sensitive to modulation by CRH 
and dexamethasone in vitro. At microarray analysis, genes 
associated with endosomal protein degradation and mem-
brane components were downregulated in USP8 mutant ad-
enomas as were AVPR1B, IL11RA, and PITX2. Inhibition of the 
ubiquitin-proteasome pathway increased ACTH secretion 
and POMC itself proved a target of ubiquitylation, indepen-
dently of USP8 sequence status. Conclusions: Our study has 
shown that USP8 mutant ACTH-secreting adenomas present 
a more “typical” corticotrope phenotype and reduced ex-
pression of several genes associated with protein degrada-
tion. Further, ubiquitylation is directly involved in intracel-
lular ACTH turnover, suggesting that the ubiquitin-protea-
some system may represent a target for treatment of human 
ACTH-secreting adenomas. © 2019 The Author(s) 
Published by S. Karger AG, Basel
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Introduction
The pathophysiology of Cushing’s disease received 
considerable impetus from the recent discovery that cor-
ticotropin (ACTH)-secreting pituitary adenomas may 
harbor somatic mutations in the ubiquitin-specific prote-
ase 8 (USP8) gene [1, 2]. Indeed, in the early months of 
2015, 2 independent investigators reported that gain-of-
function USP8 mutations can be observed in one-third of 
ACTH-secreting adenomas, leading to enhanced catalyt-
ic activity of the deubiquitinating enzyme. The ubiquitin-
protease system is deputized to peptide-specific proteo-
lytic degradation through binding of ubiquitin to target 
peptides, which are subsequently degraded by the 26S 
proteasome complex [3]. Deubiquitinases such as USP8 
are an integral part of the ubiquitin-protease complex and 
act to remove and recycle ubiquitin moieties.
The studies performed following the detection of USP8 
mutations in Cushing’s disease [1, 2] revealed that muta-
tions mostly occur in exon 14 and disrupt binding of 
14-3-3 proteins, which leads to increased deubiquitinase 
activity. As USP8 is involved in epidermal growth factor 
(EGF) receptor regulation [4] and, in turn, EGF is known 
to play a role in corticotrope tumoral development [5, 6], 
studies evaluated the role of USP8 on the EGF receptor 
system and, indeed, demonstrated that USP8 mutants in-
hibit EGF receptor degradation and increase EGF activity 
[1, 2]. These and other studies were performed on the 
murine corticotrope cell line AtT-20 or other easily trans-
fected cell lines, for example, HeLa, Cos-7, PC12, 
HEK293T cells. No study has yet evaluated the conse-
quences of USP8 mutations on human corticotrope ade-
nomas themselves. We attempted to answer this question 
with 3 different approaches: first, we evaluated ACTH se-
cretory status and POMC expression in corticotrope ad-
enoma primary cultures according to USP8 mutation sta-
tus; second, we assessed differences in the gene expres-
sion profile in USP8-mutated or wild-type corticotrope 
adenomas and; third, we evaluated whether the POMC 
peptide is itself a target for ubiquitylation and whether 
inhibition of the ubiquitin-proteasome system (UPS) af-
fects ACTH corticotrope turnover in human corticotrope 
adenomas in vitro.
Methods
Specimens
One hundred twenty-six ACTH-secreting pituitary adenomas 
were collected during transsphenoidal surgery for Cushing’s dis-
ease. The diagnosis had been established by standard criteria [7, 8] 
and series comprised 29 men and 97 women, aged from 14 to 76 
years median 40.1 years, 40% macroadenomas and 60% microad-
enomas, 23% surgical failures, and the remainder surgical remis-
sions. As per our previous publications [9–11], the presence of 
corticotrope cells in fresh adenoma specimens was assured by 
abundant ACTH secretion in primary cultures [12]; as regards for-
malin-fixed specimens, abundant POMC and absent GH, PRL, 
PIT1, LHB, FSHB expression was documented by microarray anal-
ysis [13].
USP8 Sequencing
RNA was obtained from formalin-fixed or fresh specimens. 
About 100 ng RNA was reverse-transcribed (Superscript VILO 
cDNA synthesis kit; Life Technologies, Carlsbad, CA, USA) with 
the following oligonucleotide primers: 5′ CTTGACCCAAT-
CACTGGAAC 3′ (forward); 5′TTACTGTTGGCTTCCTCTTCTC 
3′ (reverse) [14] for amplification of USP8 exon 14, the most fre-
quent site of mutations reported so far [14]. Touch-down poly-
merase chain reaction (PCR) was performed using gene ontology 
(GO) TAQ DNA polymerase (Promega, Madison, WI, USA) at 
64–57  ° C annealing. PCR products were purified by ExoProStar 
Illustra enzyme (Ge Healthcare, Chicago, IL, USA) and Sanger se-
quencing performed using the ABI PRISM Big DYE Terminator 
version 3.1 cycle sequencing kit (Applied Biosystems, Foster City, 
CA, USA) on ABI PRISM 3500 analyzer [13]. All chromatographs 
yielded informative sequencing data. Of note, USP8 sequence was 
identical in the 10 samples obtained from both fresh and formalin-
fixed specimens (1 adenoma carried the P720R mutation, all others 
wild-type USP8 sequence)
Human Pituitary Adenoma Primary Culture
Specimens were established in culture according to our usual 
protocol [12, 15] and plated at 20,000–60,000 cells per well. Pri-
mary cultures were incubated in serum-free DMEM + 0.1% bovine 
serum albumin (BSA) containing 10 nM corticotropin-releasing 
hormone (CRH) or 10 nM dexamethasone (DEX). Wells treated 
with DMEM + BSA only represented control secretion. Medium 
was collected after 4 and 24 h for measurement of ACTH; after 
24 h, RNA was extracted using Pure Link RNA mini kit (Invitro-
gen, Carlsbad, CA, USA).
Proteasome Inhibition
Adenomas were incubated with 0.01–100 nM carbobenzoxy-L-
leucyl-L-leucyl-L-leucinal MG132, a peptide aldehyde that selec-
tively inhibits chymotrypsin-like proteolysis [16, 17]. Medium was 
collected and cell content extracted after 24 h for ACTH assay [18].
ACTH Assay
ACTH was measured by immunometric assay (Diasorin S.p.A. 
Saluggia, Italy) with all samples from the same specimen assayed 
in the same run. Intra-assay coefficient of variation is 7.9% and as-
say sensitivity is 1.2 pg/mL. Given the considerable variability in 
ACTH adenoma concentrations [12], responses were normalized 
to percent of secretion in wells incubated with DMEM + BSA only 
(control = 100%) for statistical analyses.
Ubiquitin-ACTH Co-Immunoprecipitation
Total protein content was extracted by RIPA Lysis buffer (25 
mM Tris-HCl pH 7.6, 150 mM NaCl, 1%, NP-40, 1% sodium de-
oxycholate, 0.1% SDS; Thermo Scientific, Rockford, IL, USA) sup-
USP8 Mutations in ACTH-Secreting 
Pituitary Adenomas
121Neuroendocrinology 2020;110:119–129
DOI: 10.1159/000500688
plemented with protease and phosphatase inhibitor cocktail (Sig-
ma Aldrich, St. Louis, MO, USA). Protein concentration was mea-
sured using Bradford assay (BioRad, Hercules, CA, USA). Cell 
lysates (150 µg) were incubated at 4  ° C overnight with anti-ubiq-
uitin rabbit polyclonal primary antibody (1: 2,000 dilution, Abcam, 
Cambridge, UK) and nonimmune IgG (i.e., nonspecific control). 
Ubiquitin-precipitated cell extracts were captured on Protein A/G 
PLUS-agarose (Santa Cruz Biotechnology Inc., Dallas, TX, USA) 
then separated on SDS-PAGE using a 4–12% gradient (NuPage gel 
in Tris-glicine, Life Technologies, Carlsbad, CA, USA) under de-
naturing conditions. Proteins were transferred to Hybond ECL ni-
trocellulose membrane (GE Healthcare, Little Chalfont, UK) and 
the membrane blocked with 5% non-fat milk, incubated with anti-
ACTH rabbit polyclonal antibody against the entire 1–39 sequence 
(1: 1,000 dilution Abcam, Cambridge, UK), followed by incubation 
with horseradish peroxidase-conjugated secondary goat poly-
clonal anti-rabbit antibody (1: 10,000 dilution; Invitrogen, Ca-
marillo, CA, USA). Blots were developed using enhanced chemi-
luminescence technique. Bioinformatic prediction of ubiquity-
lation sites on human POMC protein sequence (GenBank 
Accession # AAH65832) was performed at www.ubpred.org.
Microarray Analysis from Archival Specimens
RNA was extracted from formalin-fixed paraffin-embedded 
adenomatous samples using Recover All Total Nucleic Acid Isola-
tion Kit (Life Technologies, Carlsbad, CA, USA), as previously de-
scribed [13]. Samples were subjected to RNA quality control, that 
is,  reverse-transcription and real-time PCR amplification of ribo-
somal protein L13A (RPL13A) [19], using Taqman probe 
Hs03043885_g, (Applied Biosystem, Foster City, CA, USA). All 
samples yielded the expected 81 bp transcript at < 30 cycles, attest-
ing to adequate quality RNA. RNA (300 ng) was analyzed on Hu-
man HT_12 v4 Bead Chip (Whole Genome DASL High Through-
put assay, Illumina, San Diego, CA, USA). Fluorescence was im-
aged and data captured into HiScan, a high-resolution laser 
imager (Illumina, San Diego, CA, USA). Array data have been de-
posited at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token 
=itsvwwkuzjyvpsj&acc=GSE93825.
Differentially Gene Expression Analysis
Genome studio software (Illumina, San Diego, CA, USA) was 
used to assess differential expression after rank invariant normal-
ization (Genome Studio, Illumina, San Diego, CA, USA). Only 
genes with Benjamini and Hochberg p value ≤0.05 were consid-
ered and Diff Scores calculated based on p value transformation 
according to the difference between average signals in mutant and 
wild-type specimens. Volcano plot [20] was used to illustrate dif-
ferential expression: magnitude of over- and underexpression of a 
given gene versus the significance of the comparison.
Functional Annotation and GO
Two approaches were used to extract biological features from 
gene lists: DAVID version 6.7 [21] was used to annotate and clas-
sify significant genes and perform functional annotation cluster-
ing. Minimum value of enrichment score for significant clusters 
was 1.3. Clusters were annotated to GO project, including molecu-
lar function, cellular component, biological process, Kyoto Ency-
clopedia of Genes and Genomes, and protein information re-
source. Further, Cytoscape with Cluego plug-in [22] was used to 
identify molecular interaction networks with K score = 0.4 and 
Benjamini-Hochberg p value ≤0.001. Biological pathways includ-
ed were GO project, Kyoto Encyclopedia of Genes and Genomes, 
and Inter Pro for protein domains [23]. 
Real-Time PCR
RNA (100 ng) was reverse transcribed (Superscript-Vilo cDNA 
synthesis kit; Life Technologies, Carlsbad, CA, USA) and quantita-
tive real-time PCR performed on a 7900 HT sequence Detection 
System (Applied Biosystem, Foster City, CA, USA), using Plati-
num Quantitative PCR Supermix-UDG with premixed ROX. Taq-
man assay (Applied Biosystem, Foster City, CA, USA) was used for 
quantification of the following genes: POMC (probe Hs00174947_
m1), CRH-R1 (probe Hs01062290_m1), NR3C1, that is, glucocor-
ticoid receptor (probe Hs00230813_m1) and RPLP0, that is, 
housekeeping gene (probe Hs99999902_m1). Basal expression 
data (2–ΔCt) were calculated and normalized to RPLP0; expression 
after treatments was analyzed as 2–ΔΔCt and expressed in fold 
change from baseline [9].
The following probes were used for validation experiments: 
AP1G2 (Hs00960175_g1) for downregulated genes and CMTM8 
(Hs00418243_m1) for upregulated genes. Expression data (2–ΔCt) 
were normalized to RPLP0; validation was carried out in 15 USP8 
mutant and 16 wild-type specimens not used for microarray anal-
ysis.
Statistical Analysis
Differences between specimens harboring USP8 mutant or 
wild-type sequence were established by ANOVA, Mann-Whitney 
test, or χ2 test, as appropriate, using Statview 4.5 (Abacus Con-
cepts, Berkeley, CA, USA). Significance was accepted for p < 0.05, 
and data are given as mean ± SEM.
Results
USP8 Mutation Carriers
Out of 126 adenomas, 29 carried heterozygous USP8 
mutations. Eighteen specimens carried missense muta-
tions in p.S718 or p.P720; 10 adenomas presented the 
p. S719 deletion, and one adenoma carried a novel 15-bp 
deletion (p.P720_723 del). Specimens from female pa-
tients were more likely to present USP8 mutations com-
pared to specimens from male patients (28.9 vs. 3.5%, p < 
0.005) as only one adenoma from a male patient present-
ed a p.P720R mutations. Age (38.5 ± 2.45 vs. 40.6 ± 1.46 
years, NS) as well as size of the adenoma (48.2 vs. 37.1% 
macroadenomas, NS) was comparable among USP8 mu-
tant and wild-type sequence carriers.
USP8 Mutant Adenomas Secrete More ACTH and 
Are More Sensitive to Corticotrope Modulators
Primary cultures were available in 84 ACTH-secreting 
adenomas: 59 wild type for USP8 and 25 USP8 mutation 
carriers (8 with p.S719 deletion, 16 with p.P720 and 
p.S718 missense mutations and 1 adenoma with 
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p.P720_723 deletion). Spontaneous 24 h ACTH secretion 
was significantly greater in specimens carrying USP8 mu-
tations compared to wild-type adenomas as was POMC 
expression (Fig. 1).
In regard to the response to CRH stimulation, USP8 
mutant adenomas presented a more marked response to 
CRH, as assessed in terms of percent increase (Fig. 2) and 
absolute increase (4 h: 5.79 ± 2.23 ng/10,000 cells vs. 1.30 
± 0.52 ng/10,000 cells, p < 0.005; 24 h: 10.8 ± 3.63 vs. 3.23 
± 1.51 pg/10,000 cells, in USP8 mutant vs. wild-type, re-
spectively, p < 0.0005). Further, expression CRH-R1 was 
greater in USP8 mutation carriers (0.153 ± 0.04 vs. 0.070 
± 0.023 normalized expression, respectively, p < 0.005). 
Changes in POMC during incubation with CRH were not 
associated with USP8 mutation status (24 h: 1.37 ± 0.158 
vs. 1.198 ± 0.264 fold change from baseline, respectively, 
NS). CRH stimulation had been performed during the 
diagnostic work-up in 68 patients, 13 carrying USP8 mu-
tant and 55 USP8 wild-type adenomas. No correlation be-
tween in vivo and in vivo responses was observed for ei-
ther group (r = 0.336, NS and r = 0.157, NS for USP8 mu-
tant and wild-type adenomas, respectively). 
In addition, USP8 mutation carriers appeared more 
sensitive to the inhibitory effect of dexamethasone than 
USP8 wild-type specimens, assessed as percent from con-
trol (Fig. 2) and absolute decrease (–2.42 ± 1.41 vs. –0.62 
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± 0.51 ng/10,000 cells at 24 h, in USP8 mutant versus 
wild-type, respectively, p < 0.05). No differences were ob-
served after 4-h incubation with dexamethasone (174.9 ± 
93.29 vs. 120.4 ± 17.77% control, NS, 0.13 ± 0.18 vs. –0.09 
± 0.09 ng/10,000 cells, respectively, NS), in keeping with 
the modest effect of dexamethasone after short-term in-
cubation in adenomatous cells in vitro [12], nor in the 
effect of dexamethasone on POMC expression (24 h: 0.74 
± 0.068 vs. 0.94 ± 0.149 fold change from baseline, respec-
tively, NS). Interestingly, NR3C1 was expressed at greater 
levels in USP8 mutation carriers compared to USP8-wild-
type adenomas (0.94 ± 0.084 vs. 0.50 ± 0.085 normalized 
expression, respectively, p < 0.005). High dose dexameth-
asone testing had been performed in 63 patients, 14 car-
rying USP8 mutant and 49 USP8 wild-type adenomas. As 
for CRH, no correlation between in vivo and in vivo re-
sponses was observed (r = –0.307, NS and r = 0.368, NS 
for USP8 mutant and wild-type adenomas, respectively).
Analysis of ACTH secretion and POMC expression in 
basal and modulated conditions in adenomas carrying 
different USP8 mutations, that is,  p.S718, p.S719, and 
p.P720, did not reveal clear-cut differences according to 
the affected amino acid (spontaneous ACTH concentra-
tions: F = 0.619, NS:, POMC expression: F = 0.673, NS:, 
ACTH change during CRH incubation: F = 0.997, NS:, 
ACTH change during DEX incubation: F = 0.419, NS). 
USP8 Mutant Adenomas Present a Different Gene 
Expression Profile
Comparisons of gene profiles in 5 USP8 mutant vs. 
34 wild-type specimens allowed identification of over- 
or underexpressed genes according to USP8 status. 
Volcano plot (Fig.  3) shows genes upregulated with diff 
score ≥13 and genes downregulated with diff score ≤–13 
in USP8 mutant vs. USP8 wild-type adenomas. Compari-
son of gene profiles revealed that 2 genes, CMTM8 (CKLF-
like MARVEL transmembrane domain containing 8) and 
MAPK15 (mitogen-activated protein kinase 15), both 
 involved in EGF signaling, were upregulated in USP8 
 mutation carriers. One hundred forty-four genes were 
downregulated in USP8 mutant compared to wild-type ad-
enomas (online suppl. Table 1; for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000500688), which 
allowed functional analysis. Cytoscape revealed major 
clustering of downregulated genes in pathways related to 
endoplasmic reticulum-associated protein degradation, 
response to topologically incorrect proteins, Golgi-associ-
ated vesicle, ribosomal large subunit biogenesis, endosome 
membrane recycling, and cell-to-cell junction (Fig. 4). The 
latter 2 biological functions were also identified by DAVID 
with 58 genes included in the membrane component (en-
richment score 1.56, p = 0.0026) and 7 genes in the cell-to-
cell adhesion component (enrichment score 1.3, p = 0.013). 
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Validation of over- and underexpressed genes was car-
ried out in a separate set of 15 USP8 mutant and 16 USP8 
wild-type adenomas. Quantitative RT-PCR for CMTM8 
and APIG2 (adaptor-related protein complex 1 gamma 2 
subunit) confirmed overexpression and underexpression 
in USP8 mutant adenomas compared to wild-type speci-
mens, respectively (Fig. 5). 
Proteosome Inhibition Increases ACTH Levels
Incubation with MG132, an inhibitor of the ubiquitin-
protease pathway, was performed in 11 adenomatous 
specimens (7 USP8 wild-type and 4 USP8 mutation car-
riers). ACTH concentrations in both medium and cell 
content increased significantly during MG132 incuba-
tion (Fig.  6), indicating that proteosomal degradation 
plays a role in maintaining ACTH corticotrope turnover. 
No significant differences were observed between USP8 
mutant (2 with p.S719del, 1 with p.P720_723del and 1 
with p.P720R) and wild-type adenomas (1 nM MG132: 
ACTH in medium: F = 1.96, NS, ACTH content: F = 
0.056, NS; 10 nM MG132: ACTH in medium: F = 0.08, NS, 
ACTH content: F = 0.014, NS; remaining comparisons all 
NS).
POMC Is a Target of Ubiquitylation
In order to identify whether the POMC/ACTH pep-
tide is a direct target of the UPS, as we have recently 
shown in rat corticotropes [18], we performed ubiquitin/
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ACTH co-immunoprecipitation. Western blotting on 
ubiquitin-precipitated cell extracts showed that POMC 
and its precursor, 39 kDa pre-POMC, are ubiquitylated, 
whereas no band corresponding to 1–39 ACTH at 6 kDa 
was detected in ubiquitin precipitates (Fig. 7). Further, 
the same bands were evident in both USP8 mutant and 
wild-type adenomas, suggesting that deranged USP8 
function did not lead to qualitative changes in POMC/
ACTH peptides. The search for canonical ubiquitylation 
sites on the human POMC sequence revealed 5 potential 
residues with medium-high confidence, at lysine 76, 103, 
129, 177, and 215.
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Discussion
The UPS is a major player in intracellular protein deg-
radation, regulating transcription factors, membrane 
trafficking, receptor signaling, cell-cycle control among 
others [3]. Proteolytic degradation by the UPS is a multi-
step process requiring ubiquitylation of the target protein 
and detragadation by a 26S proteasome macromolecular 
complex. As with other posttranslational modification, 
ubiquitylation is reversible and specific proteases, that is, 
deubiquitinases, remove ubiquitin from tagged proteins 
thereby rescuing and recycling proteins marked for deg-
radation. The balance between ubiquitylation and deu-
biquitination determines which proteins are degraded 
and which are not, thus subserving “proteostasis” [24]. 
Most recently, mutations in a deubiquitinase, USP8, 
have been shown to occur in a subset of human cortico-
trope adenomas [1, 2, 14, 25–30], thus proving the first 
somatic mutation to be described in Cushing’s disease. 
Mutations in another deubiquitase, USP48, have also 
been recently detected in corticotrope adenomas, mostly 
wild-type for USP8 itself [31]. USP8 is one of over 80 hu-
man deubiquitinases and is mainly involved in stabiliza-
tion of endosomal sorting complexes [32] and receptor-
activated tyrosine kinase downregulation [33]. Mutations 
reported in corticotrope adenomas usually occur in exon 
14 [1, 2] and disrupt association with 14-3-3 protein and 
catalytic inactivation; it follows that most USP8 muta-
tions represent gain-of-function mutations with un-
checked, constitutive deubiquitinase activity [2].
One well-known target of USP8 is the EGF receptor 
[4], a tyrosine kinase and potent mitogen involved in cor-
ticotrope tumorigenesis [5, 6, 34–36]. Studies on cells 
transfected with mutant USP8 demonstrated higher lev-
els of EGF-R protein [1], reduced EGFR degradation, and 
enhanced EGF-R recycling [1, 2]. Further, treatment with 
the EGF-R inhibitor gefitinib attenuated ACTH secretion 
in 2 USP8 mutant but not a wild-type corticotrope ade-
noma [1]. Experiments in the murine corticotrope cell 
line AtT-20 [2] also revealed that USP8 mutant-transfect-
ed cells are more responsive to the stimulatory effect of 
EGF on both POMC transcription and ACTH secretion 
[5, 14].
Studies aimed at investigating the effect of mutant 
USP8 have been performed in cell lines and little is known 
as yet on the consequences on human corticotrope tu-
mors themselves in vitro. Our first aim was to establish 
whether USP8 status affects ACTH synthesis and secre-
tion in human pituitary ACTH-secreting adenomas in vi-
tro and we could demonstrate that, indeed, adenomas 
harboring USP8 mutations secrete markedly greater 
amounts of ACTH. Of note, plasma ACTH levels have 
been reported to be both lower [2, 25], equal [14, 26, 28], 
and higher [1] in patients harboring USP8 mutants com-
pared to wild-type USP8 carriers, attesting to the fact that 
baseline plasma ACTH is a poor indicator of corticotrope 
secretory activity [37]. ACTH synthesis in vitro was also 
increased as USP8 mutant adenomas expressed nearly 
twice as much POMC as USP8 wild-type specimens. This 
latter result tallies with findings in some 30 frozen adeno-
matous specimens, which revealed higher POMC expres-
sion in USP8 mutant vs. wild-type specimens [1, 25].
In regard to the response to CRH, USP8 mutation car-
riers exhibited a two-fold greater response than USP8 
wild-type adenomas and expressed the CRH receptor 
gene at higher amounts. In keeping with this more typical 
“corticotrope” secretory behavior, USP8 mutant adeno-
mas also appeared more sensitive to dexamethasone in-
hibition and expressed greater levels of the NR3C1 recep-
tor. Analysis of responses to CRH and high-dose dexa-
methasone in patients with USP8 mutant adenomas 
yielded superimposable responses according to USP8 sta-
tus in our hands [28], whereas greater sensitivity to high-
dose dexamethasone testing has been reported by others 
[14]. In the present series, no correlation between in vitro 
and in vivo responses in a given patient was observed for 
either USP8 mutant and wild-type carriers; this result is 
not surprising as the correlation between in vitro and in 
vivo responses to CRH and dexamethasone is good but 
by no means absolute [12].
Given these differences in the secretory profile of USP8 
mutation carriers, we decided to compare the gene ex-
pression profiles in USP8 mutant and wild-type cortico-
trope adenomas in our microarray data set [13]. Differ-
ential gene expression analysis according to USP8 status 
revealed reduced expression of genes related to pathways 
associated with protein degradation, that is, response to 
topographically incorrect protein, endoplamic reticu-
lum-associated protein degradation, in USP8 mutant ad-
enomas which is in line with reduced activity of the ubiq-
uitin-protesome system given constitutive activation of 
the USP8 deubiquitinase. The recycling endosome com-
ponent also featured among USP8 mutant downregulated 
functions in keeping with involvement of the endosome 
pathway in EGF-R recycling [2]. Further, both Cytoscape 
and DAVID identified functions related to membrane 
component and cell-to-cell adhesion among genes down-
regulated in USP8 mutant adenomas, which suggests de-
regulation in additional membrane-related pathways. 
Genes of interest in this group (online suppl. Table 1) are, 
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SCAMP2 and CDC42EP5, involved in calcium-depen-
dent granule exocytosis [38, 39], ERGIC1 and TMED9, 
associated with endoplasmic reticulum-Golgi trafficking 
[40], DERL2, required for ER-associated degradation [41] 
and APIG2, an adaptin involved in immature secretory 
granule sorting [42].
More closely pertaining to corticotrope pathophysiol-
ogy, AVPR1B, the gene encoding for the vasopressin sub-
type 3 receptor, and IL11RA, encoding for the interleukin 
11 receptor, involved in the ACTH/POMC response to 
desmopressin [11] and interleukin 11 [43], respectively, 
were among genes underexpressed in USP8 mutant ade-
nomas. PITX2, an expression factor involved in pituitary 
development, was also underexpressed in USP8 mutant 
adenomas which is of particular interest given that PITX2 
knockout mice differentiate only the corticotrope lineage 
[44]. Other genes of interest to neuroendocrine and pitu-
itary tumors which were underexpressed in USP8 mutant 
corticotrope adenomas were neuropeptide S receptor 1 
[45], fibroblast growth factor 2 antisense gene product or 
nudix hydroxylase 6 (a.k.a. GFG1) [46], and human testis 
specific protein Y-encoded 1, the latter giving rise to pro-
lactin and ACTH-secreting pituitary adenomas in trans-
genic mice [47].
Interestingly, only 2 genes, CMTM8 and MAPK15, 
proved significantly overexpressed at differential expres-
sion analysis in USP8 mutant adenomas and both are 
linked to the EGF-R pathway. Upregulation of CMTM8 
(a.k.a. CKLFSF8), a tumor suppressor, chemokine-like 
factor, might represent a compensatory adaptation to 
EGF-R activation as it has been shown to attenuate 
 EGFR-mediated signaling [48]. Likewise, MAPK15 (or 
ERK8), a member of the MAPK family, acts as corepres-
sor for EGF-activated genes such as estrogen-related re-
ceptor alpha [49]. Conversely, other MAP kinases, that is, 
MAPK12, and MAPK-associated proteins, that is, 
 MAPK8P2 and MAPK8P3, were downregulated in USP8 
mutant adenomas, suggesting tight regulation of factors 
involved in the EGF-MAPK pathway. EGFR gene expres-
sion did not differ among USP8 mutant and wild-type 
adenomas (diff score 3.027, NS), in keeping with previous 
results [1, 25]. Lastly, differential expression of USP8 it-
self did not reach significance (diff score –7.002, NS); pre-
vious results on USP8 expression were contrasting, as 
mRNA levels appeared increased in USP8 mutant adeno-
mas according to one study [25] and comparable to wild-
type in another [1]. 
As mentioned above, upon the discovery of USP8 mu-
tations in corticotrope adenomas, studies have focused 
on its effect on the EGF receptor system but we postu-
lated that ubiquitylation could target the ACTH biosyn-
thetic pathway directly. Indeed, co-immunoprecipitation 
experiments showed that POMC and its precursor pre-
POMC are direct targets of ubiquitylation. Of note, the 
POMC peptide contains several lysines, that is, canonical 
ubiquitylation sites, as well as other, potential ubiquity-
lation sites, for example, threonines, cysteines, and ser-
ines [50]. ACTH itself does not appear a target for ubiq-
uitylation but this is not surprising as it is synthesized 
downstream to the endoplasmic reticulum [51] where 
ubiquitinases are known to act [52]. Interestingly, no 
qualitative differences were observed between USP8 mu-
tant and wild-type adenomas, suggesting that the UPS 
modulates ACTH turnover in normal as well as tumoral 
corticotropes. Indeed, we have recently shown that inhi-
bition of the ubiquitin-proteasome pathway with MG132 
led to an increase in ACTH secretion and intracellular 
content in normal rat pituitary primary cultures [18]. The 
present study shows that inhibition of the ubiquitin-pro-
teasome pathway in human corticotrope adenomas leads 
to increased ACTH secretion and cell content. This could 
be observed in both USP8 mutant and wild-type adeno-
mas, indicating that gain-of-function USP8 mutations are 
not a prerequisite for sensitivity to ubiquitin-mediated 
proteolysis. Indeed, a recent study on AtT-20 cells report-
ed reduced ACTH secretion and increased apoptosis dur-
ing incubation with an USP8 inhibitor [53], supporting 
the concept that the interplay between ubiquitylation and 
deubiquitylation subserves corticotrope ACTH proteos-
tasis.
In conclusion, our study has shown that USP8 mutant 
corticotrope adenomas present a more “typical” cortico-
trope phenotype with pronounced ACTH synthesis and 
secretion and greater sensitivity to the 2 main cortico-
trope modulators, that is, CRH and glucocorticoids. Fur-
ther, we have shown that genes associated with the pro-
teosomal degradation machinery are dampened in USP8 
mutant adenomas and, at the same time, counter regula-
tory mechanisms may come into play to fine-tune the 
EGFR-MAPK pathway in these cells. In addition, the 
POMC peptide itself is a target of ubiquitylation and in-
hibition of the ubiquitin-protease pathway increased 
ACTH content and secretion supporting the concept that 
the ubiquitin system plays a direct role on ACTH synthe-
sis and processing within corticotropes, in addition to its 
effect via EGF. In fact, the hypothesis of corticotrope-spe-
cific USP8 substrates other than EGF-R had been put for-
ward by one of the first publications on USP8 mutations 
in Cushing’s disease [2].
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Altogether, this evidence indicates that the UPS is a 
key component in human corticotrope pathophysiology 
and represents a potential candidate for targeted therapy, 
acting either upon the EGF-receptor or POMC process-
ing, in ACTH-secreting adenomas. The detection of 
USP8 mutant in these adenomas [1, 2] has indeed opened 
new scenarios for Cushing’s disease.
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